Balance Sheet Sun Pharmaceutical Industries Ltd.

Equities

SUNPHARMA

INE044A01036

Pharmaceuticals

Delayed NSE India S.E. Other stock markets 03:20:05 2026-01-20 am EST			5-day change	1st Jan Change
1,624.50 ^INR	-3.04%		-6.43%	-5.55%

Jan. 19	Sun Pharma states Organon acquisition news is speculative	RE
Jan. 15	Sun Pharmaceutical Industries Limited Announces the Availability of UNLOXCYT (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma	CI

6b04c98e5d7ac2cd72ce808e049b7d89._34Zu7gZrVwie2rhTxLYPem6k3gpH84IULQLpNkTbng.qxBL6Y5J1DBKLl--DESBRJH_ohRGS7pQG9dqx7ZmNArITXiMin7kP0tDPw

Published financial data: SUN PHARMACEUTICAL INDUSTRIES LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: March	2021	2022	2023	2024	2025
Revenues	335B	387B	439B	485B	526B
Other Revenues, Total	-	-	-	-	-
Total Revenues	335B	387B	439B	485B	526B
Cost of Goods Sold, Total	92.19B	109B	113B	114B	116B
Gross Profit	243B	278B	326B	371B	410B
Selling General & Admin Expenses, Total	69.04B	73.54B	83.55B	95.02B	101B
Depreciation & Amortization - (IS)	20.8B	21.44B	25.28B	25.56B	25.75B
Other Operating Expenses	88.68B	101B	124B	145B	158B
Other Operating Expenses, Total	179B	196B	233B	265B	284B
Operating Income	64.28B	81.47B	93.06B	105B	126B
Interest Expense, Total	-1.41B	-1.27B	-1.72B	-2.38B	-2.31B
Interest And Investment Income	4.67B	7.69B	5.31B	11.26B	12.97B
Net Interest Expenses	3.26B	6.41B	3.59B	8.88B	10.66B
Income (Loss) On Equity Invest.	-123M	-165M	-479M	-384M	-154M
Currency Exchange Gains (Loss)	236M	1.54B	-1.26B	361M	1.86B
Other Non Operating Income (Expenses)	2.89B	736M	756M	1.57B	621M
EBT, Excl. Unusual Items	70.54B	90B	95.66B	116B	139B
Restructuring Charges	-	-564M	-	-740M	-3.62B
Merger & Related Restructuring Charges	-	-	-644M	-	-
Gain (Loss) On Sale Of Investments	260M	7.7M	-240M	-102M	5.12B
Gain (Loss) On Sale Of Assets	139M	348M	75.4M	-99.7M	-164M
Asset Writedown	-156M	-2.09B	-312M	-1.56B	-71.3M
Insurance Settlements	147M	170M	133M	85M	230M
Legal Settlements	-43.06B	-1.56B	-	-	-58.2M
Other Unusual Items	-	-41.66B	-1.07B	-2.71B	-3.1B
EBT, Incl. Unusual Items	27.87B	44.65B	93.61B	110B	137B
Income Tax Expense	5.15B	10.76B	8.48B	14.39B	27.72B
Earnings From Continuing Operations	22.72B	33.89B	85.13B	96.1B	110B
Net Income to Company	22.72B	33.89B	85.13B	96.1B	110B
Minority Interest	6.31B	-1.17B	-394M	-336M	-357M
Net Income - (IS)	29.04B	32.73B	84.74B	95.76B	109B
Net Income to Common Incl Extra Items	29.04B	32.73B	84.74B	95.76B	109B
Net Income to Common Excl. Extra Items	29.04B	32.73B	84.74B	95.76B	109B
Per Share Items
Net EPS - Basic	12.1	13.64	35.32	39.91	45.55
Basic EPS - Continuing Operations	12.1	13.64	35.32	39.91	45.55
Basic Weighted Average Shares Outstanding	2.4B	2.4B	2.4B	2.4B	2.4B
Net EPS - Diluted	12.1	13.6	35.3	39.9	45.55
Diluted EPS - Continuing Operations	12.1	13.6	35.3	39.9	45.55
Diluted Weighted Average Shares Outstanding	2.4B	2.4B	2.4B	2.4B	2.4B
Normalized Basic EPS	21.01	22.96	24.76	29.98	36.07
Normalized Diluted EPS	21.01	22.96	24.76	29.98	36.07
Dividend Per Share	7.5	10	11.5	13.5	16
Payout Ratio	53.7	65.97	29.73	30.26	33.07
Supplemental Items
EBITDA	83.45B	101B	117B	129B	150B
EBITA	72.11B	90.48B	105B	116B	138B
EBIT	64.28B	81.47B	93.06B	105B	126B
EBITDAR	83.87B	102B	117B	129B	150B
Total Revenues (As Reported)	343B	396B	445B	499B	545B
Effective Tax Rate - (Ratio)	18.47	24.09	9.05	13.03	20.18
Total Current Taxes	9.57B	3.54B	18.69B	19.89B	33.2B
Total Deferred Taxes	-4.43B	7.21B	-10.22B	-5.5B	-5.48B
Normalized Net Income	50.4B	55.08B	59.4B	71.93B	86.54B
Interest on Long-Term Debt	185M	159M	332M	370M	338M
Non-Cash Pension Expense	104M	102M	136M	155M	213M
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	21.03B	21.33B	23.08B	31.28B	31.54B
Net Rental Expense, Total	420M	535M	589M	734M	777M
Imputed Operating Lease Interest Expense	77.97M	211M	198M	276M	511M
Imputed Operating Lease Depreciation	342M	324M	391M	459M	267M
Maintenance & Repair Expenses, Total	5.28B	5.25B	6.57B	7.8B	8.11B
Stock-Based Comp., SG&A Exp. (Total)	-	-	-	-	-
Total Stock-Based Compensation	-	-	-	-	-

Fiscal Period: March	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	62.73B	45.08B	46.24B	92.86B	103B
Short Term Investments	32.59B	44.69B	60.04B	53.71B	45.36B
Trading Asset Securities, Total	310M	36.77B	45.02B	44.33B	113B
Total Cash And Short Term Investments	95.63B	127B	151B	191B	261B
Accounts Receivable, Total	90.98B	106B	115B	113B	131B
Other Receivables	7.37B	4.01B	4.14B	6.19B	2.96B
Notes Receivable	560M	1.7B	413M	650M	484M
Total Receivables	98.91B	112B	119B	119B	134B
Inventory	93.62B	93.11B	110B	103B	108B
Prepaid Expenses	2.79B	2.86B	3.72B	4.14B	3.75B
Other Current Assets, Total	13.48B	15.8B	15.02B	17.32B	19.62B
Total Current Assets	304B	350B	399B	435B	526B
Gross Property Plant And Equipment	202B	212B	230B	239B	248B
Accumulated Depreciation	-90.39B	-100B	-116B	-126B	-136B
Net Property Plant And Equipment	112B	112B	114B	113B	113B
Long-term Investments	64.82B	52.15B	54.57B	64.41B	46.98B
Goodwill	62.88B	65.49B	87.13B	85.99B	89.39B
Other Intangibles, Total	56.61B	60.28B	93.27B	86.66B	90.21B
Accounts Receivable Long-Term	306M	194M	108M	-	-
Loans Receivable Long-Term	7.1M	7.1M	6.1M	8.5M	27.9M
Deferred Tax Assets Long-Term	35.56B	28.97B	31.64B	41.04B	44.08B
Other Long-Term Assets, Total	40.35B	29.07B	28.34B	28.77B	11.38B
Total Assets	677B	698B	807B	855B	921B
Liabilities
Accounts Payable, Total	39.74B	44.79B	56.82B	56.53B	61.84B
Accrued Expenses, Total	11.97B	14.83B	15.13B	16.89B	18.86B
Short-term Borrowings	24.45B	4.69B	59.58B	28.44B	18.67B
Current Portion of Long-Term Debt	4.24B	2.32B	2.4B	-	-
Current Portion of Leases	1.02B	1.08B	1.28B	1.26B	1.37B
Current Income Taxes Payable	1.79B	1.78B	3.09B	4.12B	7.33B
Unearned Revenue Current, Total	1.67B	1.93B	1.57B	1.27B	1.34B
Other Current Liabilities	76.58B	101B	59.21B	61.34B	72.53B
Total Current Liabilities	161B	172B	199B	170B	182B
Long-Term Debt	6.55B	2.3B	-	13.3M	25.2M
Long-Term Leases	2.43B	2.52B	5.6B	3.02B	3.56B
Unearned Revenue Non Current	7.19B	6.19B	5.7B	4.89B	3.77B
Pension & Other Post Retirement Benefits	2.89B	3.43B	3.26B	4B	4.53B
Deferred Tax Liability Non Current	445M	319M	317M	1.55B	1.92B
Other Non Current Liabilities	915M	575M	335M	254M	395M
Total Liabilities	182B	187B	214B	184B	196B
Common Stock, Total	2.4B	2.4B	2.4B	2.4B	2.4B
Additional Paid In Capital	11.87B	11.87B	11.87B	11.87B	11.87B
Retained Earnings	402B	412B	472B	537B	615B
Comprehensive Income and Other	48.47B	53.48B	73.67B	84.94B	93.38B
Total Common Equity	465B	480B	560B	637B	722B
Minority Interest	30.17B	30.55B	33.2B	34.39B	2.68B
Total Equity	495B	511B	593B	671B	725B
Total Liabilities And Equity	677B	698B	807B	855B	921B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	2.4B	2.4B	2.4B	2.4B	2.4B
ECS Total Common Shares Outstanding	2.4B	2.4B	2.4B	2.4B	2.4B
Book Value / Share	193.65	200.1	233.38	265.35	300.99
Tangible Book Value	345B	354B	380B	464B	543B
Tangible Book Value Per Share	143.85	147.68	158.19	193.39	226.14
Total Debt	38.69B	12.9B	68.86B	32.74B	23.62B
Net Debt	-56.95B	-114B	-82.44B	-158B	-238B
Debt Equivalent of Unfunded Proj. Benefit Obligation	1.6B	1.99B	2.08B	2.98B	3.42B
Debt Equivalent Oper. Leases	3.36B	4.28B	4.71B	5.87B	6.22B
Minority Interest, Total (Incl. Fin. Div)	30.17B	30.55B	33.2B	34.39B	2.68B
Equity Method Investments, Total	2.61B	2.66B	3.89B	4.43B	4.49B
Account Code - Inventory Valuation	6	6	6	6	6
Inventories - Raw Materials, Total	32.86B	28.42B	34.33B	31.01B	33.87B
Inventories - Work In Process, Total	18.29B	20.58B	24.97B	20.1B	20.19B
Inventories - Finished Goods, Total	37.74B	39.75B	44.52B	46.1B	46.23B
Inventories - Others	1.07B	1.22B	1.31B	1.48B	2.14B
Land - (BS)	4.43B	6.45B	6.68B	8.17B	7.86B
Buildings, Total	57.07B	57.84B	61.4B	63.61B	65.67B
Machinery, Total	124B	132B	140B	146B	152B
Full Time Employees	37K	38K	41K	43K	43K
Assets under Capital Lease - Gross	-	-	-	-	-
Assets under Capital Lease - Accumulated Depreciation	-	-	-	-	-
Assets on Operating Lease - Gross	16.9M	-	-	-	-
Assets on Operating Lease - Accumulated Depreciation	-2M	-	-	-	-
Accumulated Allowance for Doubtful Accounts (Supple)	2.41B	3.69B	4.15B	4.06B	3.26B

Fiscal Period: March	2021	2022	2023	2024	2025
Net Income	29.04B	32.73B	84.74B	95.76B	109B
Depreciation & Amortization - CF	12.47B	12.08B	12.75B	13.76B	13.45B
Amortization of Goodwill and Intangible Assets - (CF)	7.83B	9.01B	12.02B	11.15B	11.62B
Depreciation & Amortization, Total	20.3B	21.09B	24.77B	24.91B	25.07B
Amortization of Deferred Charges, Total - (CF)	504M	436M	533M	662M	681M
(Gain) Loss From Sale Of Asset	16.7M	1.66B	227M	1.66B	235M
(Gain) Loss on Sale of Investments - (CF)	-2.6B	3.13B	6.2M	-922M	-2.51B
Asset Writedown & Restructuring Costs	-	-88.7M	-10M	-1.5M	-
Stock-Based Compensation (CF)	-	-	-	-	-
Provision and Write-off of Bad Debts	43.1M	176M	2.07B	906M	1.81B
Other Operating Activities, Total	-11.24B	15.13B	-6.12B	-12.25B	9.38B
Change In Accounts Receivable	937M	-13.42B	-9.53B	3.53B	-16.02B
Change In Inventories	-10.8B	3.07B	-12.02B	5.99B	-1.84B
Change In Accounts Payable	3.81B	3.7B	11.82B	2.5B	5.28B
Change in Other Net Operating Assets	31.69B	22.24B	-46.89B	-1.39B	9.34B
Cash from Operations	61.7B	89.85B	49.59B	121B	141B
Capital Expenditure	-11.7B	-14.95B	-20.86B	-22.02B	-21.29B
Sale of Property, Plant, and Equipment	971M	606M	210M	308M	610M
Cash Acquisitions	-616M	-7.4B	-46.86B	-1.43B	-2.73B
Divestitures	-	238M	-	-	-
Investment in Marketable and Equity Securities, Total	13.73B	-37.91B	-16.44B	9.32B	-38.64B
Net (Increase) Decrease in Loans Originated / Sold - Investing	882M	63.6M	-	-207M	286M
Other Investing Activities, Total	2.09B	2.1B	4.5B	7.12B	8.7B
Cash from Investing	5.36B	-57.25B	-79.44B	-6.9B	-53.06B
Short Term Debt Issued, Total	-	1.06B	-	1.43B	-
Long-Term Debt Issued, Total	66.03B	16.57B	81.6B	45.73B	33.62B
Total Debt Issued	66.03B	17.63B	81.6B	47.16B	33.62B
Short Term Debt Repaid, Total	-1.73B	-	-1.3B	-	-482M
Long-Term Debt Repaid, Total	-109B	-45.29B	-30.34B	-82.29B	-44.78B
Total Debt Repaid	-111B	-45.29B	-31.65B	-82.29B	-45.27B
Issuance of Common Stock	-	-	-	-	-
Repurchase of Common Stock	-560M	-	-	-	-
Common Dividends Paid	-15.59B	-21.59B	-25.19B	-28.98B	-36.14B
Common & Preferred Stock Dividends Paid	-15.59B	-21.59B	-25.19B	-28.98B	-36.14B
Other Financing Activities, Total	1.25B	-2.69B	-1B	-2.99B	-31.27B
Cash from Financing	-59.8B	-51.93B	23.76B	-67.1B	-79.06B
Foreign Exchange Rate Adjustments	-1.3B	1.27B	1.57B	-740M	1.23B
Miscellaneous Cash Flow Adjustments	-	414M	5.67B	12.9M	-300K
Net Change in Cash	5.96B	-17.65B	1.15B	46.62B	9.83B
Supplemental Items
Cash Interest Paid	1.44B	732M	992M	2.19B	2.24B
Cash Income Tax Paid (Refund)	10.03B	-9.69B	15.1B	15.69B	4.77B
Levered Free Cash Flow	84.29B	74.05B	7.91B	75.83B	82.4B
Unlevered Free Cash Flow	85.17B	74.85B	8.99B	77.32B	83.84B
Change In Net Working Capital	-35.9B	-17.35B	53.62B	-8.02B	-591M
Net Debt Issued / Repaid	-44.9B	-27.65B	49.95B	-35.13B	-11.65B

Fiscal Period: March	2021	2022	2023	2024	2025
Profitability
Return on Assets	5.91	7.41	7.73	7.91	8.87
Return on Total Capital	7.25	9.63	9.81	9.63	10.85
Return On Equity %	4.61	6.74	15.42	15.2	15.71
Return on Common Equity	6.33	6.93	16.29	16.01	16.09
Margin Analysis
Gross Profit Margin %	72.48	71.86	74.21	76.41	78.02
SG&A Margin	20.61	19.03	19.04	19.59	19.12
EBITDA Margin %	24.91	26.24	26.55	26.55	28.47
EBITA Margin %	21.53	23.41	23.94	23.99	26.18
EBIT Margin %	19.19	21.08	21.2	21.69	23.97
Income From Continuing Operations Margin %	6.78	8.77	19.4	19.82	20.85
Net Income Margin %	8.67	8.47	19.31	19.75	20.79
Net Avail. For Common Margin %	8.67	8.47	19.31	19.75	20.79
Normalized Net Income Margin	15.05	14.25	13.53	14.83	16.46
Levered Free Cash Flow Margin	25.16	19.16	1.8	15.64	15.67
Unlevered Free Cash Flow Margin	25.43	19.36	2.05	15.94	15.95
Asset Turnover
Asset Turnover	0.49	0.56	0.58	0.58	0.59
Fixed Assets Turnover	2.99	3.46	3.9	4.28	4.66
Receivables Turnover (Average Receivables)	3.62	3.92	4	4.27	4.32
Inventory Turnover (Average Inventory)	1.05	1.16	1.12	1.08	1.1
Short Term Liquidity
Current Ratio	1.89	2.04	2	2.56	2.89
Quick Ratio	1.2	1.38	1.36	1.82	2.17
Operating Cash Flow to Current Liabilities	0.38	0.52	0.25	0.71	0.77
Days Sales Outstanding (Average Receivables)	100.89	93.06	91.32	85.72	84.42
Days Outstanding Inventory (Average Inventory)	349.04	313.32	325.82	340.07	332.43
Average Days Payable Outstanding	133.76	142.51	142.27	192.62	179.69
Cash Conversion Cycle (Average Days)	316.18	263.87	274.88	233.17	237.16
Long Term Solvency
Total Debt/Equity	7.82	2.53	11.61	4.88	3.26
Total Debt / Total Capital	7.25	2.46	10.4	4.65	3.16
LT Debt/Equity	1.82	0.94	0.94	0.45	0.49
Long-Term Debt / Total Capital	1.68	0.92	0.85	0.43	0.48
Total Liabilities / Total Assets	26.88	26.84	26.54	21.48	21.3
EBIT / Interest Expense	45.45	63.97	54.1	44.12	54.48
EBITDA / Interest Expense	59.8	80.54	68.5	54.56	65.32
(EBITDA - Capex) / Interest Expense	51.52	68.8	56.38	45.33	56.12
Total Debt / EBITDA	0.46	0.13	0.58	0.25	0.16
Net Debt / EBITDA	-0.67	-1.11	-0.7	-1.22	-1.57
Total Debt / (EBITDA - Capex)	0.53	0.15	0.71	0.3	0.18
Net Debt / (EBITDA - Capex)	-0.78	-1.3	-0.85	-1.46	-1.83
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	2.01	15.39	13.53	10.51	8.42
Gross Profit, 1 Yr. Growth %	4.84	14.41	17.24	13.78	10.7
EBITDA, 1 Yr. Growth %	21.71	21.56	14.75	10.51	16.25
EBITA, 1 Yr. Growth %	22.96	25.48	16.03	10.73	18.33
EBIT, 1 Yr. Growth %	29.91	26.75	14.1	13.05	19.82
Earnings From Cont. Operations, 1 Yr. Growth %	-45.53	49.15	151.17	12.89	14.1
Net Income, 1 Yr. Growth %	-22.87	12.7	158.91	13.01	14.12
Normalized Net Income, 1 Yr. Growth %	75.77	9.28	7.72	21.1	21.39
Diluted EPS Before Extra, 1 Yr. Growth %	-22.89	12.4	159.56	13.03	14.16
Accounts Receivable, 1 Yr. Growth %	-3.43	16.64	9.08	-1.72	15.99
Inventory, 1 Yr. Growth %	13.21	-0.54	18.72	-6.14	4.51
Net Property, Plant and Equip., 1 Yr. Growth %	-0.49	-0.02	1.65	-0.47	-0.26
Total Assets, 1 Yr. Growth %	-0.86	3.15	15.67	5.84	7.72
Tangible Book Value, 1 Yr. Growth %	6.45	2.66	7.74	21.12	17.02
Common Equity, 1 Yr. Growth %	2.65	3.33	16.63	13.7	13.43
Cash From Operations, 1 Yr. Growth %	-5.86	45.61	-44.8	144.69	15.96
Capital Expenditures, 1 Yr. Growth %	-24.12	27.77	39.5	5.57	-3.33
Levered Free Cash Flow, 1 Yr. Growth %	130.38	-12.14	-89.55	858.5	8.66
Unlevered Free Cash Flow, 1 Yr. Growth %	121.35	-12.12	-88.25	760.42	8.44
Dividend Per Share, 1 Yr. Growth %	87.5	33.33	15	17.39	18.52
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	7.35	8.5	14.46	12.01	9.46
Gross Profit, 2 Yr. CAGR %	8.35	9.52	15.82	15.5	12.23
EBITDA, 2 Yr. CAGR %	13.66	21.64	18.16	12.61	13.34
EBITA, 2 Yr. CAGR %	15.49	24.22	20.72	13.34	14.46
EBIT, 2 Yr. CAGR %	16.48	28.32	20.32	13.57	16.39
Earnings From Cont. Operations, 2 Yr. CAGR %	-15.84	-9.87	93.55	68.39	13.49
Net Income, 2 Yr. CAGR %	4.38	-6.77	70.82	71.06	13.57
Normalized Net Income, 2 Yr. CAGR %	40.87	38.59	8.56	14.22	20.71
Diluted EPS Before Extra, 2 Yr. CAGR %	4.41	-6.9	70.8	71.28	13.59
Accounts Receivable, 2 Yr. CAGR %	1.2	6.13	12.22	3.54	6.77
Inventory, 2 Yr. CAGR %	6.45	6.11	8.24	5.56	-0.96
Net Property, Plant and Equip., 2 Yr. CAGR %	1.06	-0.26	0.81	0.59	-0.37
Total Assets, 2 Yr. CAGR %	2.27	1.13	9.24	10.65	6.8
Tangible Book Value, 2 Yr. CAGR %	8.91	4.54	4.87	14.77	19.01
Common Equity, 2 Yr. CAGR %	5.93	2.99	9.78	15.16	13.57
Cash From Operations, 2 Yr. CAGR %	67.61	17.08	-10.35	16.22	68.45
Capital Expenditures, 2 Yr. CAGR %	-39.65	-1.53	33.5	21.36	1.03
Levered Free Cash Flow, 2 Yr. CAGR %	45.64	42.27	-69.36	0.09	222.73
Unlevered Free Cash Flow, 2 Yr. CAGR %	53.19	39.47	-67.52	0.54	205.46
Dividend Per Share, 2 Yr. CAGR %	65.14	58.11	23.83	16.19	17.95
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	8.24	9.97	10.15	13.13	10.8
Gross Profit, 3 Yr. CAGR %	9.21	10.33	12.04	15.13	13.88
EBITDA, 3 Yr. CAGR %	14.44	16.23	19.33	15.55	13.81
EBITA, 3 Yr. CAGR %	16.68	18.73	21.46	17.29	14.98
EBIT, 3 Yr. CAGR %	16.26	19.81	23.44	17.85	15.62
Earnings From Cont. Operations, 3 Yr. CAGR %	-3.68	1.85	26.84	61.71	47.9
Net Income, 3 Yr. CAGR %	11.48	7.08	31.05	48.85	49.47
Normalized Net Income, 3 Yr. CAGR %	30.68	29.44	27.47	12.59	16.21
Diluted EPS Before Extra, 3 Yr. CAGR %	11.62	7.01	31.03	48.84	49.62
Accounts Receivable, 3 Yr. CAGR %	5.2	6.1	6.74	7.37	7.53
Inventory, 3 Yr. CAGR %	10.81	4.06	9.87	3.22	5.21
Net Property, Plant and Equip., 3 Yr. CAGR %	1.79	0.7	0.38	0.38	0.3
Total Assets, 3 Yr. CAGR %	1.6	2.56	5.76	8.09	9.68
Tangible Book Value, 3 Yr. CAGR %	7.75	6.78	5.39	10.37	15.48
Common Equity, 3 Yr. CAGR %	6.64	5.05	7.35	11.07	14.58
Cash From Operations, 3 Yr. CAGR %	16.45	59.93	-8.88	25.29	16.13
Capital Expenditures, 3 Yr. CAGR %	-15.81	-22.51	10.59	23.46	12.5
Levered Free Cash Flow, 3 Yr. CAGR %	34.14	23.06	-39.98	-3.46	2.87
Unlevered Free Cash Flow, 3 Yr. CAGR %	30.88	27.29	-38.42	-3.17	3.11
Dividend Per Share, 3 Yr. CAGR %	55.36	53.78	42.19	21.64	16.96
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	3.57	4.31	10.69	10.78	9.87
Gross Profit, 5 Yr. CAGR %	2.23	3.81	11.81	12.37	12.11
EBITDA, 5 Yr. CAGR %	-0.48	0.67	15.91	14.79	16.9
EBITA, 5 Yr. CAGR %	-1.28	0.19	18.28	16.57	18.61
EBIT, 5 Yr. CAGR %	-3.14	-1.01	17.87	17.3	20.57
Earnings From Cont. Operations, 5 Yr. CAGR %	-16.68	-15.45	27.34	24.54	21.32
Net Income, 5 Yr. CAGR %	-8.57	-14.02	32.24	29.15	23.76
Normalized Net Income, 5 Yr. CAGR %	8.06	2.88	21.34	23.14	24.72
Diluted EPS Before Extra, 5 Yr. CAGR %	-8.52	-14.04	32.33	29.16	23.76
Accounts Receivable, 5 Yr. CAGR %	6.07	8.06	7.95	4.85	6.75
Inventory, 5 Yr. CAGR %	6.4	3.78	9.77	4.5	5.41
Net Property, Plant and Equip., 5 Yr. CAGR %	4.92	2.11	1.4	0.65	0.08
Total Assets, 5 Yr. CAGR %	4.03	2.59	4.59	5.73	6.18
Tangible Book Value, 5 Yr. CAGR %	7.79	6.21	6.59	9.78	10.85
Common Equity, 5 Yr. CAGR %	7.09	5.55	7.88	8.98	9.79
Cash From Operations, 5 Yr. CAGR %	-1.59	4.87	4.88	40.75	16.51
Capital Expenditures, 5 Yr. CAGR %	-19.23	-16.54	1.24	-7.28	6.66
Levered Free Cash Flow, 5 Yr. CAGR %	51.67	20.6	-25.69	13.8	17.63
Unlevered Free Cash Flow, 5 Yr. CAGR %	44.68	19.08	-25.05	16.33	16.86
Dividend Per Share, 5 Yr. CAGR %	49.63	23.36	41.88	37.47	31.95